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Eosinophilic colitis (EC) is a rare inflammatory disease included in the chapter of eosinophilic 
gastrointestinal disorders (EGIDs), diagnosed by the presence of primary eosinophilic infiltrate in 
the colon wall in symptomatic patients. While the aetiology of primary colonic eosinophilia is 
unknown, several conditions are involved in the pathogenesis of secondary eosinophilic colonic 
infiltrate (food allergens, parasitic infections, drugs), which have to be excluded in order to 
correctly diagnose the primary form of the disease. Up to now, EC is lacking of codified guidelines 
regarding diagnostic criteria (especially eosinophil threshold values) and treatment, thus a correct 
approach to EC remains very challenging. Imaging, laboratory tests and endoscopy might be helpful 
in ruling out other mimic conditions, but EC is still a diagnosis of exclusion. Several treatment 
options are feasible, but most of the evidences are drawn from case reports and small case series, 
thus limiting their value. We carried out a review of the current literature to evaluate the more 








































































Eosinophilic colitis (EC) is a rare inflammatory disease, included in the chapter of eosinophilic 
gastrointestinal disorders (EGIDs), and characterized by a high eosinophilic infiltrate in the colonic 
wall, with unknown causes.1, 2, 48, 56 The definition of EC is still disputed. On the basis of the recent 
international literature, the term “eosinophilic colitis” should be reserved to symptomatic patients, 
whereas asymptomatic patients with a significant increase in colonic eosinophils should receive a 
diagnosis of “primary colonic eosinophilia” (PCE).3 Nevertheless, PCE remains a poorly 
characterized condition, even less than EC itself, that pathologists may consider when “greater than 
normal” numbers of eosinophils are found in colonic mucosa.2 For EC, there are no clear threshold 
values for eosinophils at this moment; matter of fact, even the normal number of eosinophils in 
colonic mucosa has not been clearly defined yet.34  
In this narrative review we report the updated evidence from literature, so to deeply examine 
etiology, pathophysiology, diagnostic criteria and therapeutic strategies of this condition. 
 
Epidemiology 
Primary eosinophilic colitis is considered to be a rare disease. Since there are no standardized 
diagnostic criteria, it is unclear the real frequency in the general population.1, 5 A US database 
review performed on about 35 million people reported a prevalence of 2,1/100,000 persons. EC 
seems to be more common in adults (2,3/100 000) than in children (1,6/100 000) with a slightly 
higher ratio in women and in caucasian individuals.5 Other studies seem to show a bimodal age 
distribution, firstly in neonates and secondly in adulthood.6, 7 It is known that EC, such as other 
EGIDs, is more common in urban and suburban areas versus rural areas and in patients with a 
higher level of education.8 It has been shown that EC is associated with a wide spectrum of allergic 






























































Today all the physiologic functions of eosinophils are still not completely known,10 making the 
pathogenesis of EC poorly understood.4 Eosinophils are by far more common in tissue than in blood 
and in the GI tract usually reside in the lamina propria of the small intestine, except the squamous 
epithelium of the esophagus.11 They are involved in several functions, especially in protection 
against bacterial and parasites, regulation of the intestinal microbiome and tissue homoeostasis.9 
Eosinophils are activated by several stimuli including allergens, bacterial and parasites infections 
and they are regulated by variety of cytokines, such as interleukin (IL)-5, IL-13, IL-4 and tumor 
necrosis factor (TNF), mostly produced by activated Th2 T-lymphocytes and mast cells.12, 13 Once 
activated, eosinophils release cytotoxic proteins, Leukotriene C4 (LTC4) and several other 
cytokines that modulate the immune system by activating dendritic cells, inducing immunoglobulin 
(Ig)A-class switching in B cells and promoting their survival.10 It is general thought that several 
factors such as genetic predisposition, dysbiosis, and the environment (i.e. allergens) play a pivotal 
role in EGIDs, but the clear understanding of their relationship is still unknown.4 EC 
pathophysiology is related to age of onset. In infants, it seems to be an IgE-associated disorder since 
it has been reported in association with breast-feeding protein hydrolysate formula-feeding. Instead, 
in adults it is more likely due to a Th2 T-lymphocyte driven response.1 Studies have found 
association with autoimmune disorders such as inflammatory bowel diseases (IBD),14 celiac 
disease,15 rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis and inflammatory 
myositis.16, 17 This suggest a possible role of allergen-related immune dysregulation.18 
 
Clinical features 
The clinical presentation of EC is heterogeneous and usually non-specific. An acute presentation is 
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common in adults and it is usually associated with abdominal pain and/or chronic watery diarrhea.1 
Several other symptoms are commonly associated with EC, such as heartburn, dysphagia, nausea 
and vomiting, abdominal pain, unjustified weight loss, ascites, volvulus/intussusception, GI 
perforation, obstruction or haemorrhage.5 Since EC is frequently associated with history of atopy, 
other symptoms or diseases might be present, including asthma, food sensitivities, rhinitis or 
eczema.21, 22  
The eosinophilic infiltration can be located in various layers and depth of bowel wall. Three 
patterns have been described, that can be simultaneously present in the same patient.19 Mucosal 
disease (Type 1) is the most common and is usually associated with diarrhea, bleeding (which can 
lead to iron-deficiency anaemia) and protein losing enteropathy. Transmural disease (Type 2), much 
rarer, in which the eosinophilic infiltrations is widespread along the wall and usually associated 
with wall thickening and/or strictures that can lead to GI obstructions, volvulus and perforations.21 
Subserosal disease (Type 3) is limited to external part of the bowel wall and is usually associated 
with eosinophilic ascites and/or bloating.20 
Type 1 EC clinical course is typically continuous, defined by chronic persistent GI symptoms for 
more than 6 months, without period of remission. Type 2 EC is associated with recurring course, 
defined by at least 2 flares of the disease, separated by a period without digestive symptoms. Type 3 
EC is the most benign since it is usually associated to a single flare, defined by clinical symptoms 
present for <6 months associated with the absence of any relapse after initial flare.23 EC in infants is 
mostly benign, since it is widely associated with food-related allergy and the elimination of the 
allergen is enough to resolve the disease within few days. In adolescent or older onset, the course 































































Since EC is part of EGIDs, diagnosis of EC should match the same criteria, namely: (1) presence of 
GI symptoms; (2) histologic evidence of eosinophilic infiltration; and (3) ruling out other causes of 
tissue eosinophilia (Secondary EC).23 
Laboratory findings might be helpful to suspect EC along the clinic, but typically they are not 
adequate for EC diagnosis alone. Peripheral eosinophilia (defined as an absolute count of > 500 
eosinophils/µL) can be present up to 80% of patients.24 Moreover, Type 3 EC is more frequently 
associated to hypereosinophilia and is also considered as risk factor for frequent relapse 
phenotype.22 As in EGIDs, an increase in serum IgE is common in about 75% of cases.25 Since EC 
has a strong correlation with IgE-mediated pathological responses, allergic skin testing (AST) and 
radioallergosorbent tests (RAST) might be useful in allergic-EC forms (both ingested or inhaled 
allergens), although AST shows a high false-positive rate (i.e. low specificity) and low sensitivity.1 
Non-IgE Th2 dependent allergy tests (skin patch) might be more useful in adolescent and adults, 
although show similar limitations as RAST and AST.42 Faecal calprotectin is a reliable non-invasive 
tool to assess intestinal inflammation,37 but has shown no help in diagnosing EC since its value is 
usually within the normal limit range.38 This might be related specifically to the inflammatory 
infiltrate type, poor in neutrophils, whose cytosol contains calprotectin.39, 40 
Radiology and imaging studies might be helpful, although findings are usually not specific both in 
children and adults. EC radiological findings are nodularity of the wall, colonic wall thickening 
(usually circumferential and located from ascending to the descending colon), “halo sign” (due to 
layering of the bowel wall) and “araneid-limb-like”. This latter sign is usually located in ascending 
and transverse colon and it is due to contrast enhancement of mucosal sinuses in the longitudinal 
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Endoscopic appearance of EC is variable and, in most cases, similarly to microscopic colitis shows 
normal mucosa;57 several non-specific endoscopic findings might be present, such as erythematous 
patchy mucosa, ulcers, polyps and pseudo-polyps.3,26  
Histology is considered the gold-standard, but the clear cut-off for normal eosinophilic counts are 
not yet defined as well as for other EGIDs such as eosinophilic esophagitis.28, 29 Because eosinophils 
are normally present in colonic mucosa of both children and adults and their number depends of 
several factors, such as age, region, climate, alimentary diet, drugs use and so on.32 Several studies 
have tried to address valid cut-offs, 3, 30, 31 and the latest evidence shows that reasonable cut-off 
might be >50/high-power field (HPF) in right colon, >35/HPF in the transverse colon and > 25/HPF 
in the left colon.3 EC is diagnosed with sheets or clusters of eosinophils located in the lamina 
propria with minimal acute and chronic inflammation. These clusters may show cryptitis 
degranulation and/or crypt abscesses and might be found also in muscularis mucosa, submucosa or 
both.27 Since the patchy distribution nature of the disease, multiple endoscopic biopsies are required 
but, unfortunately, there are no formal guidelines for histological diagnosis.33 Some authors suggest 
to take at least 5-6 biopsies from both abnormal and normal endoscopic mucosa in terminal ileum 
and in each colonic segment.34, 34, 35 Surgical biopsies should be considered the best option, since 
they provide a full thickness sample, in order to fully discriminates between the three types of EC, 
but this is a more invasive procedure, limited to selected cases.36 
Once colonic eosinophilic infiltration has been confirmed, it is important to rule out secondary 
conditions that lead to hypereosinophilia in order to establish a correct diagnosis. The differential 
diagnosis is wide and includes conditions like parasitic infections (i.e. Strongyloides stercoralis, 
Schistosoma spp, Trichuris trichiura, Angiostrongylus costaricencis, Gnathostoma spp, Ascaris 
lumbricoides, Ancylostoma caninum, Ascaris suum, Enterobius vermicularis and Dientamoeba 
fragilis), drugs (i.e. non-steroidal anti-inflammatory drugs, antiplatelet agents, carbamazepine, 
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estroprogestinic agents), vasculitis (i.e. Churg-Strauss syndrome, polyarteritis nodosa), connettive 
tissue diseases (i.e. scleroderma, dermatomyositis, and polymyositis), IBD, celiac disease, 
myeloproliferative disorders (i.e. hypereosinophilic syndrome) and malignancies (chronic 
eosinophilic leukaemia, systemic mastocytosis, malignant lymphoma; GI adenocarcinomas might 
occasionally show a brisk eosinophilic response and EC might be associated with graft-vs-host 
disease in bone marrow transplanted patients).41 
A resume of the diagnostic workflow is represented in figure 1. 
 
Treatment 
Since EC is a rare disease, actually there are no strong evidence on available treatments. In fact, 
most of the evidence are drawn from small uncontrolled case series and case reports.4 In general, 
EC tends to be more aggressive in adolescent and adults, while in infants is rather more benign and 
usually resolves within days after removing the food-allergen implicated.1 
Food-eliminating diet (i.e. removal of milk, wheat, soy, eggs, nuts, and shellfish) is considered the 
first-line non-pharmacological therapy in EGIDs,32 but its role seems to be really effective only in 
children with EC,44 whereas there is no clear evidence in adults.26 Furthermore, the usefulness of 
diet is limited by the poor compliance in older children and adults.4 
The use of corticosteroids is considered the first-line pharmacological therapy if dietary approach is 
impractical or failed to achieve a valid response.32 Their beneficial effects are related to their ability 
to inhibit eosinophil growth factors (i.e. IL-3, IL-5 and Granulocyte-macrophage colony-stimulating 
factor - GM-CSF).33 There are no randomized controlled trials to date on the efficacy of steroids in 
EC. Oral prednisone (20–40 mg per day) for 2 weeks has been shown to induce clinical remission in 
most patients,45 however some reports suggested even the need of higher doses (0·5–1 mg/kg).32 
Maintenance treatment might be required in patients in whom EC relapses during/after drug 
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minimum dose effective in maintaining clinical response), although possible undesirable long-term 
side-effects are always to be considered.46 Budesonide might be a reasonable alternative, thanks to 
its low biodisponibility (3-9 mg per day).47 
Steroid-spare agents are also a good choice in patients who requires maintenance therapy or fails to 
respond to corticosteroids. Mesalazine has been used in some cases 2. Immunomodulatory agents 
such as azathioprine/6-mercaptopurine or anti-TNF agents (i.e. infliximab, adalimumab) have been 
tried in severe, steroid-refractory or steroid-dependent EC with good results.48, 49 Other options 
might include mast-cell stabilisers (i.e. sodium cromoglycate and ketotifen),50 and the leukotriene 
receptor antagonist (montelukast),1 although their role in EC has yet to be evaluated.51, 52 A novel 
antibody directed against C-C chemokine receptor type 3 (CCR3), an eotaxin receptor expressed by 
eosinophils that facilitates their recruitment to sites of inflammation, has been shown to decrease 
eosinophilic inflammation and diarrhea in a mouse model of eosinophilic gastroenteritis.53 
Since human body harbors between 10 trillion and 100 trillion microbial cells (called microbiota), 
which is approximately equal to 10 times the total number of body cells, and considering that the 
major part is located in GI tract, 58 it is logical to try to cure colonic diseases acting on microbiota 59 
and to hypothesize its potential role in several extraintestinal diseases mediated by an impaired 
permeability.60-66 Faecal microbiota transplantation has proven efficacy in the treatment of 
inflammatory diseases of the gut. It has been reported that this treatment, in addition to oral 
corticosteroids, successfully cured a patient with severe refractory eosinophilic enterocolitis. 
However, it is unclear whether faecal microbiota transplantation could cure definitively EC and 
maintain the long-term clinical remission without the use of corticosteroids.54  
Surgery, performed as segmental colonic resection (without clear evidence if prefer primary 
anastomosis rather than diversion) should be limited to patients with complications of intestinal 
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setting of an acute abdomen, symptoms might respond to conservative management with 
immunosuppression.32, 50  
Conclusions 
EC is a rare disease, which still lacks the correct understanding of its pathophysiology and 
structured guidelines for diagnosis (especially clear cut-off values) and treatment. Unfortunately, 
there are very few studies which address these needs up to now. Therefore, several larger case-
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